Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT04313608 : A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy,Treatment | Blood / Myeloma / LymphomaB-Cell Non Hodgkin Lymphoma,Diffuse Large Cell Lymphoma

Trial Overview Read MoreRead more

This phase I trial is evaluating the safety and effectiveness of two targeted therapy drugs, each given in combination with chemotherapy for the treatment of diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) that has got worse or not responded to prior treatment.
 

This trial is treating patients with diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) .

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

Commercial Sponsor

Hoffmann-La Roche

Summary

Eligible patients will be assigned to one of two experimental arms of the trial (Arm A or Arm B). In Arm A, patients will receive up to 8, 21-day cycles of glofitamab in combination with gemcitabine and oxaliplatin, followed by up to 4 cycles of glofitamab monotherapy. In this Arm, a single dose of obinutuzumab will be administered 7 days prior to the first dose of glofitamab. In Arm B, patients will receive up to 8 cycles of mosunetuzumab in combination with gemcitabine and oxaliplatin, administered in 21-day cycles.

Recruiting Hospitals Read MoreRead more

Monash Health Haematology Research Unit
Clayton
Ms Micheleine Uhe
Micheleine.Uhe@monashhealth.org
03 9594 4044

St Vincent's Hospital, Haematology Oncology Research
Fitzroy
Ms Lisa Demosthenous
lisa.demosthenous@svha.org.au
03 9231 3182

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next